Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure

详细信息    查看全文

• 作者：Jos&eacute ; M. Andreu-Cayuelas^a ; Francisco J. Pastor-P&eacute ; rez^a ; Carmen M. Puche^b ; Alicia Mateo-Martí ; nez^c ; Arcadio Garcí ; a-Alberola^a ; Pedro J. Flores-Blanco^a ; Mariano Vald&eacute ; s^a ; Gregory Y.H. Lip^d ; Vanessa Roldá ; n^e ; Sergio Manzano-Ferná ; ndez^a ; ^f ; ^{sergiomanzanofernandez@gmail.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Anticoagulants ; Renal function ; Dosing ; Heart failure ; Atrial fibrillation
• 刊名：Revista Española de Cardiología (English Edition)
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：69
• 期：2
• 页码：134-140
• 全文大小：314 K

文摘

Renal impairment and fluctuations in renal function are common in patients recently hospitalized for acute heart failure and in those with atrial fibrillation. The aim of the present study was to evaluate the hypothetical need for dosage adjustment (based on fluctuations in kidney function) of dabigatran, rivaroxaban and apixaban during the first 6 months after hospital discharge in patients with concomitant atrial fibrillation and heart failure.

Methods

An observational study was conducted in 162 patients with nonvalvular atrial fibrillation after hospitalization for acute decompensated heart failure who underwent creatinine determinations during follow-up. The hypothetical recommended dosage of dabigatran, rivaroxaban and apixaban according to renal function was determined at discharge. Variations in serum creatinine and creatinine clearance and consequent changes in the recommended dosage of these drugs were identified during 6 months of follow-up.

Results

Among the overall study population, 44% of patients would have needed dabigatran dosage adjustment during follow-up, 35% would have needed rivaroxaban adjustment, and 29% would have needed apixaban dosage adjustment. A higher proportion of patients with creatinine clearance < 60 mL/min or with advanced age (≥ 75 years) would have needed dosage adjustment during follow-up.

Conclusions

The need for dosage adjustment of nonvitamin K oral anticoagulants during follow-up is frequent in patients with atrial fibrillation after acute decompensated heart failure, especially among older patients and those with renal impairment. Further studies are needed to clarify the clinical importance of these needs for drug dosing adjustment and the ideal renal function monitoring regime in heart failure and other subgroups of patients with atrial fibrillation.